Neoadjuvant IBI110 and Sintilimab In Combination With Chemotherapy In Resectable Locally Advanced Head And Neck Squamous Cell Carcinoma (HNSCC)- a Phase Ib Clinical Trial
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; IBI 110 (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 25 Feb 2025 Planned number of patients changed from 20 to 27.
- 25 Feb 2025 Status changed from active, no longer recruiting to recruiting.
- 19 Jul 2024 New trial record